RN3161 for Overweight and Obesity

Inclusion Criteria: * BMI: Obesity: BMI ≥ 30 kg/m² for participants with no Asian ancestry and ≥ 27.5 kg/m² for participants with Asian ancestry that has been stable (± 5%) for the previous 3 months (based on participant self-report or available medical records), with or without a weight-related comorbidity (excluding diabetes) Overweight: BMI 27 to \<30 kg/m² for participants with no Asian ancestry and 23.0 to \<27.5 kg/m² for participants with Asian ancestry that has been stable (± 5%) for the previous 3 months (based on participant self-report or available medical records), with at least 1 weight-related comorbidity (excluding diabetes) Weight-related comorbidities include a diagnosis of the following: * Hypertension: seated BP ≤ 140/90 mm Hg; receiving ≤ 2 stable (≥ 4 weeks) agents limited to ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, or thiazide ≤ 25 mg, or untreated * Dyslipidemia: stable use of lipid-lowering agents for dyslipidemia (LDL-C \< 150 mg/dL, triglycerides \< 300 mg/dL) * Osteoarthritis Exclusion Criteria: * self-reported or documented weight gain or loss \>5% within 3 months prior to screening * use of GLP1R agonists within 6 months of screening * intolerance to GLP-1 medications in the past * use of non-GLP1R medications for weight loss within 3 months of screening * HbA1c \>6.5% * diagnosis of significant liver disease * history of malignancy or anaphylaxis * use of any siRNA agent in the prior 12 months